Member Info for inanaco

I understand ... but from Scancells point of view its about "breaking Tolerance" which is why you only want to activate T cells that promote Inflammation otherwise you could promote T regulatory CD4 which calm the response

I keep saying it........ the delay what Knowlesi is moaning about is not a delay it was the Key to making sure our CD4 phenotype was directed at TH1 pro inflammatory . and Lindy played with the adjuvants to get this area Right the resultant """Hydrophobic Peptide conjugate""" has become a complex structure to build ... but the vaccine is so advanced and devastating in the mouse model its worth it ...

the value increase in the IP when you move from 70% of mice to 100% of mice ... is massive when you put that into context against Keytruda or Opdivo at 30%

this is what the market is not looking at ... only the "delay"

What the RA research reveals for Investors is that the Mechanism of Action to kill cancer cells developed for Moditope can be seen in RA

"""""As we will discuss later in this review, the PAD enzymes that affect protein citrullination are up-regulated in response to stress and other environmental factors. Therefore, it is clear that the generation and recognition of citrullinated epitopes is an early event in the disease process that plays a prominent role in the loss of self-tolerance in RA."""

Anti-citrullinated protein antibodies (ACPAs)

that's what they test for in RA

Its a advanced adaptive response Crumbs in autoimmune ...but unlike Moditope it also has antibodies which cause havoc,

Disagree as much as you like .. your post contains way to many "understatements" and contradicts itself

""" I don't disagree the share price is to cheap """

"" and I understand why the sell off has continued""

is a huge contradiction

researcher 1 .. CFD as many as you like chap .. but you cannot prove your CFD is directed linked to a share buy or sell

Ruck

If i put cancer vaccine on the end will that help .. ?

Because the science is so great .. New Buyers stepping in now .. don't have to wait years ... they don't have to study the science, so when it does take off .. they will not care about the delay in 2015 .. or if David Evans had issues in 2016 etc etc ...... so New buyers when they come and they will ... drive it up again ..

as everyone keeps saying the science is so good what is wrong with the share price .. one can assume that hang on its a bit cheap .. and drive it back up again

its the way it works, but we have Rock Solid data in immunobody ... and fantastic mouse data with Moditope ..

tick tock

only been three knock backs

1/ ... the fist ever production of SCIB1 went out of Tolerance after about 6 years ... wow!
2/ Ichor ... delay with the new Gun then knocked back from the FDA .. as far as we are aware the data is in the FDA now and all should be ok ..
3/ was developing out Moditope ... and because the technology behind that to achieve astonishing results now in the mouse model the vaccine became difficult to scale up requiring Lindy to step in and design a new process which they have done .. so it just a time delay but the value of that once proven, adds billions because of the sheer number of targets the moditope program can hit.

In other words the lead Modi1 vaccine has set us up for a trouble free development of modi2 and 3

The issue is the Market is "valuing" delay, its seeks a scapegoat .. oh it's his or her fault .. when in reality its business, it's what happens .. when you are at the forefront of a Brand new type vaccine ...

its never been done before .. a Cytotoxic CD4

I have said it before Shareholders take it down ... Not the BOD. not the Buyer ... shareholders !! if they don't understand it , why do you expect to convince buyers when you are all moaning ...

some moan and sell, others moan because they did not ... be positive Scancell have cleared the issues ..

so why should the share continue to fall ?

Ruck

This board is meant to be discussing Scancell, the investment, the commercials, the science - anything to do with Scancell.

you can google that to ...

scancell RNS on news that can have a materially influence of the SP ....

the market moves on not having news that can materially impact the SP

can you spot the difference C7 ...

On a very similar principle ....

Many investors wonder how financial spread-betting companies make money when they don’t charge brokerage on bets placed. IG Group Holdings PLC (OTC: IGGHY), a spread-betting company in the United Kingdom, reported GBP £569 million ($751.2 million) from global trading revenue in the 2018 financial year. How do these companies generate a profit? And how does a trader select the right broker? Following is a look at how financial spread-betting companies create revenue.

Revenue From the Spread
First and foremost, spread-betting companies make revenue through the spreads they charge clients to trade. In addition to the usual market spread, the broker typically adds a small margin, meaning that a stock normally quoted at $100 to buy and $101 to sell, may be quoted $99 to sell and $102 to buy in a spread bet. The buy price is always higher than the sell price, ensuring the broker makes a profit from the spread, whether the client wins or loses.

The A Book and the B Book
Brokers categorize clients into their A or B books. Traders who have a track record of losing money are placed into the broker's B book. Bets from B-book clients are not sent to the market; instead, the company actively bets against them. In this scenario, the broker stands to win when the client loses, and vice versa. Given that 90% of traders lose their deposits within six months, this model has proven to be extremely profitable.

There is, however, some risk involved with backing B-book clients. Spread-betting companies have risk limits, and if too many clients bet in one direction, these limits are breached. Brokers must then hedge their bets to restore risk to an acceptable level. Brokers avoid hedging B-book clients unless absolutely necessary, because they are effectively paying for another spread, increasing bottom line costs.

A-book clients are a similarly dependable stream of revenue, and provide opportunities to capture commissions. They trade large enough that risk is substantially lower than B-book clients, and they often enjoy a relationship in which they are trusted to expose the market (and not the broker) to risk. Such clients are often charged a premium on the standard spread, or a specially negotiated fee.

https://www.reuters.com/article/us-swiss-snb-brokers-idUSKBN0KP1EH20150116

lol county .. counter ...

do you understand something called county party risk ?

its a bad position if the market goes against you and you can't pay .even if Ig purchased the underlying asset and you default on a loss Ig is liable for the leveraged position ... which is what happened to the Traders in the swiss currency a few years ago .. they defaulted .. leaving the counter party in default ..

i repeat again your Trade is NOT backed by the underlying asset ,,, Its up to IG to hedge the outer balance position

ie ... if they do not have shorts open on scancell ... then they may hedge the position by buying the asset

so to make a claim that this is your trade is not possible ... you just do not know ..

because YOU have a Contract for difference .. Not a Contract to buy or sell the underlying asset

As IG states

""""""""""" We hedge only when overall client exposure is skewed in one direction """""""""""

https://www.ig.com/uk/how-does-ig-make-money

SCLPspWed 12:08
just bought £10K at 6.8 so average now 7.3 - CRAZY DISCOUNT RATES!

CFD ...

cannot see your name against them ..

are these ones, you have closed the Buy positions ? at a loss the £10,000 trade ?

Scancell is an IP generating company .. its not a Trading company ... so its only attributed cost if it ceased development is IP maintenance .. So Scancell can never be a Flybe ... its asset is the IP .. not a jet plane ...

Scancell don't salt the roads .... LOL

or catch the fragments of lemmings at the bottom ... and empty the pockets off ..